BRISTOL-MYERS SQUIBB PRESENTS PHASE III DATA DEMONSTRATING THAT...
• Results of the HALLMARK-Dual study include data among genotype 1b cirrhotic and non-cirrhotic, treatment-naive, non-responder, and peginterferon/ribavirin ineligible and intolerant patients • Study...
View ArticleNEW STUDY INVOLVING 10 CANADIAN RESEARCH SITES SHOWS HIGH CURE RATES FOR...
• All-oral, 12-week treatment in UNITY-2 trial achieves 98% cure rate in treatment-naïve and 93% in treatment-experienced patients with cirrhosis when used with ribavirin and 93% and 87% respectively...
View Article
More Pages to Explore .....
